BREAKING | June 11, 2026 | Business & Economy
₹98,000 Crore. All Cash. The Biggest Deal India Inc. Has Ever Done. And It Just Changed The World’s Pharma Map.
On April 27, 2026, Dilip Shanghvi — the son of a medicines distributor from Gujarat who built Sun Pharma from a single product in a rented facility in Vapi — announced a deal that made the global pharmaceutical industry stop and stare. His company, Sun Pharmaceutical Industries, was acquiring Organon & Co., a US-listed global healthcare company, for $11.75 billion — approximately ₹98,000 crore — in an all-cash transaction. It is the largest outbound acquisition ever made by an Indian company. It is the largest biopharma deal globally in 2026. And it is the moment Indian pharma stopped being a manufacturer for the world and became a consolidator of it.
The Deal in Numbers
Sun Pharmaceutical Industries and Organon & Co. announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$14.00 per share in an all-cash transaction with an enterprise valuation of US$11.75 billion. Upon successful consummation of the transaction, Sun Pharma is poised to be among the top 25 global pharmaceutical companies with combined revenue of US$12.4 billion, a leading player in Established Brands and Branded Generics, a more innovative medicines focused company with 27% revenue share, a top 3 company in global Women’s Health creating a commercial platform for future growth, the 7th largest global biosimilar player, and a company with presence in 150 countries with 18 large markets each generating over US$100 million in revenues.
One hundred and fifty countries. $12.4 billion in combined revenue. Top 3 in Women’s Health globally. Seventh largest biosimilar player on the planet. These are not the numbers of an Indian generic medicines company anymore. These are the numbers of a genuine global pharmaceutical powerhouse — and it was built in India.
What Is Organon — And Why Did Sun Pharma Want It?
Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021, to house its biosimilars and women’s health products. Big Pharma has been on a buying spree, with US companies like Gilead Sciences and Eli Lilly spending billions across sectors from cell therapy to narcolepsy. At nearly $12 billion, this latest deal is the largest outbound acquisition by an Indian pharmaceuticals firm.]
Organon is not a generics company. It operates in three high-value segments: women’s health — contraceptives, fertility treatments, menopause management — biosimilars, and established branded medicines. These are exactly the segments where Sun Pharma has wanted to grow for years but lacked the global commercial infrastructure to do so independently. With Organon, Sun Pharma does not just buy a product portfolio. It buys a sales force operating in 140+ markets, regulatory approvals across developed markets including the US and Europe, and a brand that doctors and gynecologists across the world already trust.
The Dilip Shanghvi Gamble
The all-cash deal, the largest outbound transaction by an Indian drugmaker, gives Sun Pharma access to Organon’s women’s health and specialty portfolio and a commercial presence across developed markets. The combined entity is expected to generate roughly $12.4 billion in revenue, making Sun Pharma the 7th largest biosimilar player and a Top 3 global leader in Women’s Health. “This is a coming-of-age move — the deal raises expectations for scale and capital deployment among peers,” said Salil Kallianpur, a pharma analyst.
For Dilip Shanghvi, this is the defining move of a career defined by bold, carefully calculated bets. He built Sun Pharma through decades of disciplined acquisitions — Ranbaxy in 2014, Taro Pharmaceutical in the US, Dusa Pharmaceuticals. Each deal stretched what seemed possible. But $11.75 billion in cash for a US-listed company — at a 103% premium to Organon’s pre-announcement share price — is a different order of magnitude entirely.
The Value Play: Why India Is Buying Global at a Discount
The transaction has drawn attention for its pricing. Sun is acquiring Organon at about 6 times EV/EBITDA, lower than recent domestic transactions such as Mankind Pharma’s acquisition of Bharat Serums and Vaccines and Torrent Pharmaceuticals’ buyout of JB Chemicals, which were priced at over 20 times. Analysts point out that this “value arbitrage” — where global platforms are priced significantly lower than domestic targets — is a major signal that Indian capital will increasingly flow toward overseas markets.
Six times EBITDA for a global company with 150-country presence and leadership in Women’s Health and biosimilars — versus 20+ times for domestic Indian pharma assets. That pricing gap is the single most important insight from this deal for every Indian investor and corporate strategist. The world’s most valuable pharma businesses are available to Indian buyers at fractions of what comparable Indian companies cost. Sun Pharma saw the arbitrage and acted.
What It Means for Indian Pharma
Sun Pharma’s $11.75-billion acquisition of Organon & Co. is likely to push Indian pharmaceutical companies to evaluate larger overseas acquisitions as the sector looks to expand beyond generics into specialty and branded segments. The transaction, currently the largest biopharma deal globally in 2026, represents a turning point where Indian firms act as global consolidators rather than just manufacturers.
This is the sentence that changes everything. Indian firms as global consolidators. Not manufacturers. Not contract research organisations. Not generic drug suppliers. Consolidators — the companies that buy other companies, integrate them, and emerge larger and more powerful. Tata did it in steel with Corus. Tata did it in cars with Jaguar Land Rover. Now Sun Pharma is doing it in global pharmaceuticals. The playbook is Indian. The ambition is global. And the world’s pharma industry will never look at India the same way again.
The Timeline: What Happens Next
The transaction was approved by both the Organon and Sun Pharma Boards of Directors. The deal is expected to close in early 2027, subject to customary conditions including regulatory approvals and Organon stockholder approval.
Between now and early 2027, antitrust regulators in the US, EU, and other major markets will review the combination. Given Sun Pharma’s limited overlap with Organon’s portfolio — this is an expansion deal, not a competitor merger — most analysts expect regulatory clearance to proceed smoothly. Once complete, the merged entity will immediately become one of the most geographically diverse pharmaceutical companies in the world.
The Bigger Story: India Is Now a Global Pharma Capital
India already supplies 20% of the world’s generic medicines by volume and 60% of global vaccines. It is already the pharmacy of the world in terms of manufacturing. What Sun Pharma’s Organon deal signals is the next step — India is now becoming the boardroom of global pharma, not just its factory floor.
From a rented facility in Vapi to a $12 billion global company operating in 150 countries. Dilip Shanghvi’s story is not just the story of one man or one company. It is the story of what Indian ambition, Indian capital, and Indian pharmaceutical expertise can build when given four decades and the courage to dream at a global scale.
The deal closes in early 2027. The world is already watching.
All information sourced from SEC filings, Business Today, C&EN, and Business Standard as of April 27 — June 11, 2026.
